- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01791491
Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients
June 23, 2017 updated by: Bristol-Myers Squibb
A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant
The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.
Study Overview
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles
-
Los Angeles, California, United States, 90027
- Childrens Hospital of LA
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20010
- Childrens National Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Childrens Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Male and Female subjects,12-17 years old
- Receiving CNI-based maintenance immunosuppression since the time of renal transplantation in accordance with local standard of care
- Stable renal function, in the opinion of the investigator, with a cGFR>45 mL/min/1.73m2 at the time of enrollment (per updated Schwartz Formula)
- Adolescent Recipients of a renal allograft from a living donor or a deceased donor at least 6 months prior to enrollment
- Subject must be receiving a calcineurin inhibitor (CNI)-based [cyclosporine (CsA) [any formulation] or Tacrolimus (TAC)] immunosuppressive regimen
- Subject must be receiving adjunctive background maintenance immunosuppression with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS)/mycophenolic acid (MPA)
- Subjects may be receiving maintenance corticosteroids in accordance with the local standard of care
- Negative Interferon Gamma Release Assay (IGRA) such as QuantiFERON-TB Gold test or T-Spot-TB
- FOCBP must have negative serum or urine pregnancy test within 24 hrs prior to start of study medication
- Subject must have stable estimated glomerular filtration rate (GFR) ≥45 mL/min/1.73m2 (updated Schwartz formula)
Exclusion Criteria:
- Epstein-Barr virus (EBV) serostatus negative or unknown at time of transplant and screening
- History of any treated or biopsy proven acute rejection (BPAR) within 3 months prior to enrollment
- Subjects who have experienced more than 1 episode of acute rejection (AR) of the current allograft or any antibody-mediated AR
- Subjects with any active infection [including, but not limited to, positive cytomegalovirus (CMV) or BK viral (BKV) loads, BKV associated nephropathy (BKVAN), CMV retinitis, CMV colitis, etc.]
- Urine albumin:creatinine ratio > 56.5 mg/mmol (> 0.5 mg albumin / mg creatinine) on a random voided urine specimen
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Belatacept
|
Single intravenous infusion of belatacept, 7.5 mg/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Serum Concentration (Cmax) of Belatacept
Time Frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Cmax was derived from serum concentration versus time data.
Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57.
The results were summarized.
The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).
Cmax was measured in micrograms per milliliter.
|
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Time of Maximum Observed Plasma Concentration (Tmax) of Belatacept
Time Frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Tmax was derived from serum concentration versus time data.
Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57.
The results were summarized.
The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).
Tmax was measured in hours (h).
|
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Half-Life of Elimination (T-Half) of Belatacept
Time Frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
T-HALF was derived from serum concentration versus time data.
Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57.
The results were summarized.
The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).
T-HALF was measured in hours (h).
|
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC (0-T)) and Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Belatacept
Time Frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
AUC (0 - T) and AUC (0 - INF) were derived from serum concentration versus time data and measured in microgram hours per milliliter (µg*h/mL).
Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57.
The results were summarized.
The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).
|
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Total Body Clearance (CLT) of Belatacept
Time Frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
CLT was the volume of abatacept cleared by the system, normalized by baseline body weight.
Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57.
The results were summarized.
The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).
CLT was measured in milliliters per hours per kilogram of body weight (mL/h/kg).
|
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Volume of Distribution at Steady-state (Vss) of Belatacept
Time Frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Vss was derived from serum concentration versus time data.
Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57.
The results were summarized.
The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).
Vss was measured in liters per kg body weight (L/kg).
|
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Death, Serious Adverse Events (SAEs), and Treatment-related Adverse Event (AE)
Time Frame: Date of First Dose to 24 weeks post the last dose; approximately 26 weeks
|
Death was a fatal event leading to permanent cessations of all vital functions of the body.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
Treatment related=having certain, probable, possible, or missing relationship to study drug.
|
Date of First Dose to 24 weeks post the last dose; approximately 26 weeks
|
Number of Participants With Positive Belatacept-induced Immunogenicity Response
Time Frame: Baseline/Day 1, Days 15, 29, and 57
|
Serum samples were analyzed for anti-belatacept antibodies using a validated homogenous bridging assay.
The assay followed a tiered approach consistent with health authority guidance: tier 1 for screening ADA responses, tier 2 for confirming drug specificity of the ADA-positive responses, and tier 3 for titer.
A neutralizing antibody assay was used to test those samples positive to the LEA29Y portion of the molecule in tier 2 and for which drug concentrations are =>1 μg/mL.
Lack of immunogenicity was defined as the absence of a positive response.
|
Baseline/Day 1, Days 15, 29, and 57
|
Percentage of CD86 Receptor Occupancy
Time Frame: 0.5 hours post dose on Day 1, Day 29 and Day 57
|
Blood samples collected following the single dose belatacept infusion were assessed for CD86 receptor occupancy (CD86 RO).
|
0.5 hours post dose on Day 1, Day 29 and Day 57
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2013
Primary Completion (Actual)
December 6, 2016
Study Completion (Actual)
December 6, 2016
Study Registration Dates
First Submitted
January 31, 2013
First Submitted That Met QC Criteria
February 13, 2013
First Posted (Estimate)
February 15, 2013
Study Record Updates
Last Update Posted (Actual)
July 24, 2017
Last Update Submitted That Met QC Criteria
June 23, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IM103-144
- 2011-005257-31 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant
-
University of MinnesotaWithdrawnKidney Transplant Rejection | Kidney Transplant; Complications | Kidney Transplant FailureUnited States
-
Ohio State UniversityActive, not recruitingKidney Transplant; Complications | Kidney TransplantUnited States
-
Providence Health & ServicesWashington State University; Paul I Terasaki Foundation LaboratoryUnknownKidney Transplant | Kidney/Pancreas TransplantUnited States
-
Ajay IsraniNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingKidney Transplant Rejection | Kidney TransplantUnited States
-
Hospital de Clinicas de Porto AlegreActive, not recruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant Failure | Kidney Transplant Failure and RejectionBrazil
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
-
Liverpool University Hospitals NHS Foundation TrustKidney Research United KingdomNot yet recruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant DysfunctionUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; Clinical Trials in Organ TransplantationCompletedKidney Transplant Recipients | Living-Donor Kidney TransplantUnited States
-
Singapore General HospitalRecruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant; ComplicationsSingapore
Clinical Trials on Belatacept
-
Bristol-Myers SquibbCompletedRenal TransplantationUnited States
-
Guizhou Provincial People's HospitalActive, not recruiting
-
Bristol-Myers SquibbCompletedKidney Transplantation | Chronic Kidney FailureUnited States, Argentina, Australia, Germany, Italy, South Africa, Spain, Brazil, Mexico, Belgium, France, Hungary, Switzerland, India, Canada, Austria, Czech Republic, Poland, Israel, Sweden, Turkey
-
Methodist Health SystemActive, not recruitingUse of Belatacept in Kidney Transplant PatientsUnited States
-
Bristol-Myers SquibbCompletedRenal TransplantationUnited States, Argentina, Germany, Italy, Chile, Spain, Brazil, Sweden, Belgium, France, Hungary, Australia, South Africa, Austria, Canada, United Kingdom, Poland, Czechia, Norway
-
Bristol-Myers SquibbCompletedHealthy VolunteersUnited States
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States, Netherlands, Belgium, Canada, Germany, France, Ireland, Switzerland, United Kingdom
-
Bristol-Myers SquibbTerminatedImmunosuppression in Solid Organ TransplantFrance, Germany, Italy, United States, Austria, Canada, Spain, Argentina, Brazil
-
Ain Shams UniversityRecruiting
-
East Carolina UniversityCompleted